Hyperemesis gravidarum affects 3% of pregnancies, causing severe vomiting and dehydration. Experts explain the causes, ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

The Kingdom's pharmaceutical exports increased by 14.8 per cent in 2024 compared to the previous year, reaching JD611 million ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

Company Announcement <li /> Johnson & Johnson has decided that it will not exercise its option to receive a ...

The FDA has approved Celltrion’s OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca's eculizumab (Soliris) for pediatric patients ...

The FDA has granted Priority Review to the BLA for deramiocel (CAP-1002) for the treatment of Duchenne muscular dystrophy cardiomyopathy.

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Recurrent meningitis is a rare but serious condition, occurring in about 5% of cases of community-acquired meningitis.